Mireille El Hayek, MD
Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1912139940
Payments from drug & device makers
Across 104 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$380
- Lilly USA, LLC$201
- AstraZeneca$159
- Corcept Therapeutics$117
- Abbott$115
- Sanofi-aventis U.S. LLC$83
- plus $753 from 26 others
What the payments were for
- Food & beverage$1,808100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $380 |
| Lilly USA, LLC | 12 | $201 |
| AstraZeneca(2 entities) | 9 | $159 |
| Corcept Therapeutics | 5 | $117 |
| Abbott | 7 | $115 |
| Sanofi-aventis U.S. LLC | 5 | $83 |
| Insulet Corporation | 3 | $71 |
| Dexcom, Inc. | 3 | $55 |
| Merck | 3 | $52 |
| BETA Bionics, Inc. | 5 | $48 |
| Amneal Pharmaceuticals LLC | 3 | $45 |
| Madrigal Pharmaceuticals | 2 | $40 |
| Radius Health, Inc. | 2 | $39 |
| Nevro Corp. | 2 | $32 |
| Amgen | 2 | $32 |
| Johnson & Johnson | 2 | $32 |
| Novartis | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Mannkind Corporation | 2 | $27 |
| Verity Pharmaceuticals Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Bayer | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Almatica Pharma LLC | 1 | $18 |
| Pfizer | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| GSK | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Medtronic | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
| Itamar Medical Inc | 1 | $10 |
How this compares
$1,808 in reported general payments places this provider in the 45th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $187,453 |
| JardianceEmpagliflozin | 103 | $102,394 |
| MounjaroTirzepatide | 78 | $93,310 |
| FarxigaDapagliflozin Propanediol | 92 | $88,884 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $51,507 |
| JanuviaSitagliptin Phosphate | 42 | $40,705 |
| TrulicityDulaglutide | 28 | $40,460 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $28,160 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $19,688 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $16,138 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $14,357 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $11,281 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $10,220 |
| TradjentaLinagliptin | 19 | $10,133 |
| Cinacalcet Hcl | 23 | $7,338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $380 | $191,592149 claims |
| Lilly USA, LLCMounjaro, Trulicity | $201 | $133,770106 claims |
| Boehringer IngelheimJardiance, Tradjenta | $19 | $112,527122 claims |
| AstraZenecaFarxiga | $159 | $88,88492 claims |
| MerckJanuvia | $52 | $40,70542 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $83 | $19,68813 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $45 | $4,303247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Louis
- Thomas NickolasSaint Louis$945K
- Anne GoldbergSaint Louis$830K
- Janet McGillSaint Louis$828K
- Julie SilversteinSaint Louis$536K
- Sandeep DhindsaSaint Louis$173K
- Maamoun SalamSaint Louis$170K
- Michael WhyteSaint Louis$133K
- Fumihiko UranoSaint Louis$122K
- Farid RomanSaint Louis$62K
- Kathryn DiemerSaint Louis$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.